Skip to content
Saturday 29 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,824.26
+0.29%
DAX
26,569.99
+0.77%
CAC 40
8,401.18
+0.98%
STOXX 50
6,485.67
+0.95%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 17 June 2020 7:56 am

‘Best news so far’: Matt Hancock hails steroid drug that can combat coronavirus

By: Reuters

Add as a preferred source on Google
'Best news so far': Matt Hancock hails steroid drug that can combat coronavirus
'Best news so far': Matt Hancock hails steroid drug that can combat coronavirus

Health secretary Matt Hancock today hailed the use of a steroid drug called dexamethasone for treating coronavirus patients as the best news so far of the outbreak.

Trial results announced on Tuesday showed dexamethasone, which is used to reduce inflammation in other diseases such as arthritis, reduced death rates by around a third among the most severely ill COVID-19 patients admitted to hospital.

“It does increase your chances of survival quite significantly,” Health Secretary Matt Hancock told Sky News. “It is one of the best pieces of news we’ve had through this whole crisis.”

He said that the R-rate was below 1 in all regions but did not clarify if he was speaking about England or the entire United Kingdom.

Yesterday the government gave the green light for the NHS to begin using dexamethasone immediately to treat coronavirus patients.

That followed an Oxford University clinical trial showing the steroid drug reduced the risk of death significantly in patients badly struck by coronavirus.

Read more: UK scientists make ‘major breakthrough’ as common steroid found to cut coronavirus death rate

The anti-inflammatory steroid drug has now been approved to treat all UK hospitalised coronavirus patients requiring oxygen, including those on ventilators. 

The dexamethasone trial is the first anywhere in the world to show a treatment significantly impacts coronavirus mortality.

The government had already moved to stockpile the drug, meaning it has enough to treat more than 200,000 people. Hancock has said it could save thousands of lives.

Read more

Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Politics

Related Topics

  • Coronavirus

Trending Articles

  • Pensioners to hand over bank statements in government benefits crackdown

  • Jamie Carragher: HMRC petitions for Sky Sports star to be declared bankrupt

  • Brewdog founder James Watt hits out at ‘total silence’ over new venture

  • Jamie Vardy bags Bundesliga rights as he steps up streaming war with Neville and Lineker

  • Lloyds Bank and Halifax users unable to use app in latest outage

More from Morning Wire

  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

    Business Wire
  • Limbic Becomes First AI-Led Mental Healthcare Company Selected for FDA TEMPO

    Business Wire
  • Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

    Business Wire
  • Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

    Business Wire
  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
  • Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award

    Business Wire
  • New Drill-Free Treatment Helps Patients to Feel at Ease in the Dentist Chair

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook